Experimental MASH Treatment Shows Promise in Mid-Stage Trial
Similar Articles
Existing Drugs Show Promise in Reversing Fatty Liver Disease in Animal Studies
Preclinical Study Shows Hybrid Molecule Strategy May Improve Obesity and Diabetes Treatment
Scientists Develop Drug Method to Boost Natural Killer Cells Against Multiple Cancers
Amino Acid Supplement Boosts mRNA Delivery and Gene Editing Efficiency
Endoscopic Procedure Shows Promise in Preventing Weight Regain After GLP-1 Medication Use
An experimental drug called ION224 produced meaningful liver health improvements in a mid-stage clinical trial for patients with metabolic dysfunction-associated steatohepatitis (MASH). The treatment, which works by blocking a key fat-producing enzyme, was generally well tolerated. The findings, published in The Lancet, support moving the therapy into larger Phase III trials.
Facts First
- ION224 improved liver health in 60% of patients receiving the highest dose in a Phase IIb trial.
- The drug blocks the DGAT2 enzyme to reduce the liver's production and storage of fat.
- The treatment was generally well tolerated with no serious side effects linked to the drug.
- The study is the first to show that blocking DGAT2 with this type of therapy can improve liver inflammation and fibrosis in people with MASH.
- The next research stage will be Phase III trials to confirm safety and effectiveness in a broader population.
What Happened
Researchers at the University of California San Diego (UC San Diego) School of Medicine reported that an experimental treatment called ION224 produced improvements in people with metabolic dysfunction-associated steatohepatitis (MASH). The findings, published in The Lancet, come from a Phase IIb clinical trial involving 160 adults in the United States with MASH and mild to moderate liver fibrosis. Approximately 60% of patients receiving the highest dose showed meaningful improvements in liver health compared to the placebo group. Researchers reported that ION224 was generally well tolerated with no serious side effects tied to the drug.
Why this Matters to You
MASH is an aggressive form of fatty liver disease linked to obesity and type 2 diabetes that can progress to cirrhosis, liver failure, or liver cancer. Researchers estimate that as many as one in four adults globally may have some form of fatty liver disease, with more than 100 million people affected in the United States. A safe and effective treatment could potentially benefit a large population at risk for serious liver complications. The treatment also avoided certain side effects, like dangerous increases in triglycerides, that have been seen with other drugs targeting liver fat production.
What's Next
The next stage of research will involve Phase III clinical trials to confirm the drug's safety and effectiveness in a broader population. If successful in these larger trials, ION224 could become a new treatment option for MASH.